TheStreet's Jim Cramer says the departure of a high ranking FDA official is good news for Sarepta Therapeutics (SRPT) . Dr. Ronald Farkas left the FDA for the private sector last week. Farkas was in charge of the FDA's clinical review team, which argued against the approval of Sarpeta's drug eteplirsen. Sarepta filed for approval of the drug over a year ago.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.